| Ticker: | FBTIX |
| Manager: | Rajiv Kaul |
| Manager Since: | 10/05 |
| NAV (06/17/2013): | 15.37 |
| Objective: | Equity - Sector Health |
| Peer: | HL MG |
| Net Assets ($mil): | 105.17 |
| Inception: | 12/27/2000 |
Fidelity Advisor Biotechnology Fund, Class I was incepted in December 2000 and is managed by the Fidelity Group. The objective of the fund is to seek capital appreciation. The fund normally invests primarily in common stocks. The fund normally invests at least 80% of assets in securities of companies principally engaged in the research, development, manufacture, and distribution of various biotechnological products, services, and processes, and companies that benefit significantly from scientific and technological advances in biotechnology. The fund offers dividends and capital gains twice a year in September and December.
| Stocks | 96.49% |
| Foreign Stocks | 1.54% |
| Cash | 9.98% |
| Bonds | 0.00% |
| Foreign Bonds | 0.00% |
| Preferred | 0.26% |
| Convertible | 0.04% |
| Other | -6.76% |
| Foreign Hedged | 0.00% |
| Large Growth | 50.48% |
| Large Value | 0.00% |
| Small Growth | 0.00% |
| Small Value | 0.00% |
| Foreign Stock | 50.48% |
| Emerging Market | 0.00% |
| Precious Metals | 0.00% |
| Intermediate Bond | 0.00% |
| High Yield Bond | 0.00% |
| Foreign Bond | 0.00% |
| Beta v. S&P 500 | 1.35 |
| Beta v. EAFE | -0.19 |
| Beta v. Barclays Agg Bond | 1.30 |
| Alpha 3 Yr | 13.22 |
| Alpha 5 Yr | 15.25 |
| R-Sq 3 Yr | 0.65 |
| R-Sq 5 Yr | 0.45 |
| Std Dev 3 Yr | 19.06 |
| Std Dev 5 Yr | 20.92 |
| Sharpe 3 Yr | 1.53 |
| Sharpe 5 Yr | 1.00 |
| Expense Ratio | 0.92 |
| % Max Load | NA |
| % Min Load | NA |
| % Deferred Load | NA |
| % Redemption | 0.75 |
| % Max 12 B1 Fee | 0.00 |
| % Max Mgt Fee | 0.56 |
| Min Initial Investment | 2500 |
| Min Subsequent Investment | 0 |
| 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | YTD | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NAV ($) | 5.97 | 6.70 | 7.23 | 7.49 | 7.18 | 6.34 | 7.00 | 7.78 | 9.24 | 12.02 | 15.37 |
| Total Return (%) | 33.85 | 12.22 | 7.91 | 3.59 | 2.75 | -11.69 | 10.41 | 11.14 | 18.76 | 37.46 | 26.87 |
| Annual Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Relative Performance | |||||||||||
| Rel Performance-S&P500(%) | 51.65 | 13.54 | 30.20 | -122.00 | -27.45 | 253.09 | -160.10 | -39.21 | 166.67 | 214.70 | 141.29 |
| Rel Performance-Obj.Ret.(%) | 33.11 | 34.47 | -10.52 | -1.39 | -61.15 | 119.98 | -114.66 | 31.18 | 110.18 | 182.31 | 72.90 |
| Ret.Quintile vs Obj(1 is best) | 2 | 2 | 4 | 3 | 5 | 1 | 5 | 2 | 1 | 1 | 1 |
| Turnover, Yields, and Gains | |||||||||||
| Fund Assets Net($mil) | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 6 | 39 | 105 |
| Annual Turnover (%) | 71.00 | 50.00 | 44.00 | 62.00 | 120.00 | 132.00 | 73.00 | 115.00 | 99.00 | 82.00 | 20.00 |
| Annual Dividend Paid ($) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Annual Capital Gains Paid($) | 0.00 | 0.00 | 0.00 | 0.00 | 0.53 | 0.00 | 0.00 | 0.00 | 0.00 | 0.68 | 0.00 |
| 1 Month | 3 Month | 6 Month | YTD | 1 Year | 3 Year | 5 Year | 10 Year | 15 Year | 20 Year | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Return (through 05/13) | 5.82% | 18.40% | 31.12% | 26.87% | 44.66% | 27.15% | 18.73% | 13.29% | NA | NA |
| Ret. Percentile vs. Obj. (1 is best) | 5 | 2 | 4 | 6 | 3 | 2 | 7 | 17 | NA | NA |
| Average Price/Earnings | 40.20 |
| Average Price/Book | 5.74 |
| Average EPS Growth | 15.34 |
| Average Market Value | 22,404.00 |
| Name | Weight | Shares |
|---|---|---|
| AMGEN INC | 13.10 | 284,214 |
| GILEAD SCIENCES INC | 13.06 | 365,160 |
| BIOGEN IDEC INC | 7.01 | 95,257 |
| REGENERON PHARMACEUTICALS | 4.74 | 62,604 |
| ALEXION PHARMACEUTICALS INC | 2.24 | 46,605 |
| ONYX PHARMACEUTICALS INC | 4.10 | 98,168 |
| MEDIVATION INC | 3.70 | 135,948 |
| VERTEX PHARMACEUTICALS INC | 3.64 | 141,564 |
| CELGENE CORP | 4.48 | 114,873 |